Merkel Cell Carcinoma Clinical Trials
Merkel cell carcinoma clinical trials are scientific studies through which researchers evaluate the effectiveness of new treatments and procedures. Every treatment must make its way through this process; even the current best options for skin cancer treatment were once only available through clinical trials. During this process, researchers not only study the outcomes of a particular treatment, but also the most effective dosing regimens and the best ways to counteract any potential side effects.
Ranked a Top Cancer Hospital in Nation
Moffitt is ranked 15th in the nation and is the top-ranked cancer hospital in Florida and the Southeast in Newsweek’s “America’s Best Cancer Hospitals."
Clinical trials are made possible by volunteer participants. While there is no obligation for a patient to enroll in a study, there are numerous advantages to doing so. For instance, patients may decide to enroll in Merkel cell carcinoma clinical trials in order to:
- Expand their range of treatment options
- Access novel therapies before they are widely available in other settings
- Contribute to the scientific research process
Clinical trial participants at Moffitt Cancer Center also have the unique opportunity to work with our multispecialty oncology team and highly trained research staff. Our state-of-the-art, on-site research facilities allow us to develop new therapies and evaluate their effectiveness in a single location. At Moffitt, our research studies have led to a number of significant developments, including new chemotherapy drugs and advances in the field of immunotherapy. Targeted therapies, hormone-stimulating drugs and other advanced treatments for Merkel cell carcinoma are also being evaluated through our ongoing studies.
For our efforts, we have been nationally recognized as a leader in research; Moffitt is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida.
Referrals are not required to explore Merkel cell carcinoma clinical trials with the experts at Moffitt. Call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.
-
Clinical Trials
CLINICAL TRIAL 20490
Keystroke: A Randomized Phase II Study of Pembrolizumab (Keytruda) Plus Stereotactic Re-irradiation versus SBRT Alone For Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Condition: Head & Neck
Intervention: Pembrolizumab (Keytruda)
CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)
CLINICAL TRIAL 20731
Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Condition: Cutaneous
Intervention: Afatinib (); BIBW 2992 (Afatinib)
CLINICAL TRIAL 23460
A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors
Condition: Cutaneous
Intervention: Pembrolizumab (Keytruda)
CLINICAL TRIAL 21996
An Open-Label, Multicenter, Phase 1b/2 Study of RP1 in Solid Organ Transplant Recipients with Advanced Cutaneous Malignancies
Condition: Cutaneous
Intervention: RP1 ()
CLINICAL TRIAL 21997
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Condition: Cutaneous
Intervention: Not Applicable (); Vismodegib (Erivedge)
CLINICAL TRIAL 23318
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
Condition: Sarcoma
Intervention: Pembrolizumab (Keytruda)
CLINICAL TRIAL 23360
IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Subjects with Advanced or Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: IFx-Hu2.0 (); Pembrolizumab (Keytruda)
CLINICAL TRIAL 23590
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment versus Standard-Of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
Condition: Multiple
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); Radiotherapy ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Sotorasib (); Trametinib (); VVD-159642 ()
Treatment